Abbott Laboratories vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| ABT | LLY | |
|---|---|---|
| Market Cap | $176.90 billion | $1.03 trillion |
| Revenue (TTM) | $46.59 billion | $79.67 billion |
| Net Income (TTM) | $5.42 billion | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ABT | LLY | |
|---|---|---|
| P/E Ratio | 33.28 | 38.70 |
| Price / Book | 3.42 | 30.33 |
| Price / Sales | 3.80 | 12.90 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | LLY | |
|---|---|---|
| Net Margin | 11.65% | 33.53% |
| Return on Equity | 10.48% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| ABT | LLY | |
|---|---|---|
| Dividend Yield | 2.45% | 0.60% |
| Payout Ratio | 81.55 | 23.23 |
ABT and LLY split the dividend factors evenly.
Risk & Sentiment
| ABT | LLY | |
|---|---|---|
| Short Interest | 0.57% | 1.29% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.